Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Grace Therapeutics, Inc.
13G
GRCE · 00439U104
|
13.1% |
8/7/2026
Event 8/5/2026
|
|||
| Opaleye Management Inc. | 13.1% | ||||
| Opaleye, L.P. | 13.1% | ||||
| James Silverman | 13.1% | ||||
|
Pasithea Therapeutics Corp.
13G/A
KTTA · 70261F202
|
6.1% |
7/31/2026
Event 6/30/2026
|
|||
| Opaleye Management Inc. | 6.1% | ||||
| Opaleye, L.P. | 6.1% | ||||
| James Silverman | 6.1% | ||||
|
Harrow, Inc.
13G/A
HROW · 415858109
|
6.4% |
7/31/2026
Event 6/30/2026
|
|||
| Opaleye Management Inc. | 6.4% | ||||
| Opaleye, L.P. | 6.4% | ||||
| James Silverman | 6.4% | ||||
|
SANUWAVE Health, Inc.
13G/A
SNWV · 80303D305
|
3.6% |
7/31/2026
Event 6/30/2026
|
|||
| Opaleye Management Inc. | 3.6% | ||||
| Opaleye, L.P. | 3.6% | ||||
| James Silverman | 3.6% | ||||
|
Q32 Bio Inc.
13G/A
QTTB · 746964105
|
5.5% |
7/31/2026
Event 6/30/2026
|
|||
| Opaleye Management Inc. | 5.5% | ||||
| Opaleye, L.P. | 5.5% | ||||
| James Silverman | 5.5% | ||||
|
Gossamer Bio, Inc.
13G
GOSS · 38341P102
|
5.1% |
7/29/2026
Event 7/22/2026
|
|||
| Opaleye Management Inc. | 5.1% | ||||
| Opaleye, L.P. | 4.9% | ||||
| James Silverman | 5.1% | ||||
|
Alpha Cognition Inc.
13G/A
ACOG · 02074J501
|
14.2% |
7/24/2026
Event 7/23/2026
|
|||
| Opaleye Management Inc. | 14.2% | ||||
| Opaleye, L.P. | 13.8% | ||||
| James Silverman | 14.2% | ||||
|
Rezolute, Inc.
13G/A
RZLT · 76200L309
|
6.6% |
5/11/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 6.6% | ||||
| Opaleye, L.P. | 6.4% | ||||
| James Silverman | 6.6% | ||||
|
Karyopharm Therapeutics Inc.
13G/A
KPTI · 48576U205
|
2.7% |
5/11/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 2.7% | ||||
| Opaleye, L.P. | 2.7% | ||||
| James Silverman | 2.7% | ||||
|
Sol-Gel Technologies Ltd
13G/A
SLGL · M8694L137
|
15.4% |
5/6/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 15.4% | ||||
| Opaleye, L.P. | 14.9% | ||||
| James Silverman | 15.4% | ||||
|
Codexis, Inc.
13G/A
CDXS · 192005106
|
7.5% |
5/5/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 7.5% | ||||
| Opaleye, L.P. | 7.3% | ||||
| James Silverman | 7.5% | ||||
|
Larimar Therapeutics, Inc.
13G
LRMR · 517125100
|
4.8% |
8/29/2025
Event 8/29/2025
|
|||
| Opaleye Management, Inc. | 4.8% | ||||
| Opaleye, L.P. | 4.8% | ||||
| James Silverman | 4.8% | ||||
|
Protara Therapeutics, Inc.
13G/A
TARA · 74365U107
|
4.7% |
4/28/2025
Event 3/31/2025
|
|||
|
Ocular Therapeutix, Inc
13G/A
OCUL · 67576A100
|
2.8% |
2/14/2025
Event 12/31/2024
|
|||
|
iBio, Inc.
13G/A
IBIO · 451033708
|
7.6% |
2/14/2025
Event 12/31/2024
|
|||
|
Context Therapeutics Inc.
13G/A
CNTX · 21077P108
|
0% |
2/14/2025
Event 12/31/2024
|
|||